J&J Sued for Blocking Biosimilar Remicade Competition

Generic Line
A A
A workers’ benefits fund filed a lawsuit claiming Johnson & Johnson maintained an illegal monopoly for its blockbuster drug Remicade, employing anticompetitive schemes involving insurer contracts, rebate protocols and bundling.

To View This Article:

Login

Subscribe To Generic Line